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Abstract
Over 38.0 million people live with the human immunodeficiency virus (HIV) as of 46
2019. HIV hijacks the host's cellular machinery to replicate its viral DNA and transcribe
the corresponding RNA. HIV-1 transcription relies on both cellular and viral transcription
factors for proper regulation. The viral transcriptional activator Tat is a primary regulator.
Transcription activation and elongation is controlled through the interaction of Tat with
Positive Transcription Elongation Factor b (P-TEFb), a cellular transcriptional activator.
The focus of this paper is 1) an in-depth understanding of the interaction between
P-TEFb and Tat in HIV transcription, and 2) a review of recent therapeutic approaches
for controlling HIV. First, I will describe the P-TEFb/Tat interaction involved in the
activation of HIV-1 transcription and the post-translational modifications of Tat and
P-TEFb that either inhibit or activate the complex. Then, I will discuss therapeutic
approaches used to control HIV transcription and prevent cells from remaining in
latency, and provide possible future studies for determining the efficacy of an
experimental long-acting drug.
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Introduction
Over 38.0 million people live with immunodeficiency virus (HIV) as of 2019 (1). HIV
hijacks the host's cellular machinery to replicate. HIV-1 destroys the immune system by
infecting and replicating its genome within CD4+ T lymphocytes, ultimately destroying
the cells. The viral RNA first enters into the cytoplasm of the CD4+ lymphocytes by
binding to the CD4 receptor along with the CCR5 or CXCR5 coreceptor and fusing with
the host cell (2). Therefore, HIV-1 is a lentivirus. Once the single stranded RNA is in the
cytoplasm, it is reverse transcribed into dsDNA by the viral enzyme reverse
transcriptase. In the nucleus, the dsDNA is integrated into the host genome with the
help of dsDNA preintegration complex and viral integrase (3). The integrated dsDNA
then behaves as a cellular gene and is able to direct the transcription of the viral
genome into RNA by RNA polymerase II, Tat, and positive transcription elongation
factor b (P-TEFb) (3). Differential splicing of the viral RNA transcripts leads to different
resulting viral proteins via translation (2). Either simultaneously or after being cleaved by
viral proteases into maturity, the assembled virus buds from the host cell enter into the
bloodstream (3). Figure 1 shows a schematic overview of the HIV-1 replication cycle.
Transcription of viral HIV-1 DNA initiates from the U3 promoter within the
upstream long terminal repeat (LTR) and requires the viral transactivator protein Tat for
efficient elongation (3). The cellular protein P-TEFb is recruited by Tat to the viral
transactivation response (TAR) element within the viral transcript (3). P-TEFb consists
of two subunits: cyclin-dependent kinase 9 (CDK9) and Cyclin T1. Phosphorylation of
serine 2 within the 7 amino acid repeat, YSPTSPS, of the carboxy terminal domain
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(CTD) of RNA polymerase II by CDK9 stimulates transcription elongation (3). This
results in the integrated HIV-1 DNA being transcribed into RNA within the host cell.
Understanding HIV-1 transcription is important as it is the rate determining step
of viral replication (4). The most efficient transcriptional activator is Tat, allowing viral
DNA to be turned into RNA very rapidly (4). Due to the high mutation rate within the
rapidly occurring transcription process, viral quasispecies are expected (4). This results
in HIV’s rapid acquisition of resistance to the host immune response and various
anti-HIV drugs (5). In addition, transcription is the step at which the virus maintains its
latency, meaning the viral DNA is integrated into the host’s genome, but is not actively
replicating (4, 6). By entering into latency, the viral DNA is invisible to the host immune
defense and existing antiviral drugs (6). For these reasons, it is very difficult to eradicate
HIV after a stable infection.
The focus of this thesis is 1) an in-depth understanding of the interaction
between P-TEFb and the HIV-1 transactivator Tat protein in HIV transcription, and 2) a
review of recent therapeutic approaches for controlling HIV. I will describe the
Tat/P-TEFb interaction involved in the activation of HIV-1 transcription, and the post
translational modifications of Tat and P-TEFb that either inhibit or activate the complex.
Next, I will discuss therapeutic approaches used to control HIV transcription toward
preventing HIV latency.

Structural Composition of Tat/P-TEFb Interaction
Tat Functional Domains
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Tat is a protein of 101 amino acids and is encoded in two exons (7). Exon one and two
encode residues 1-72 and 73-101, respectively (7). Within the two exons are several
critically functioning regions, which make up the activation domain, and the neighboring
arginine-rich motif, known as “ARM.” Figure 2 depicts the orientation of those functional
domains. “ARM” is composed of amino acid residues 49-57 and is essential for the
binding of Tat to TAR RNA, nuclear localization of Tat, and Tat protein stability (7). The
basic motif RKKRRQRRR makes up this region and confers the TAR RNA binding
properties to Tat, as well as the uptake of Tat by cells (7). This motif contributes to the
affinity of Tat protein to TAR RNA, but it does not dictate the specificity of binding (7).
Amino acids flanking this basic motif influence the specificity of the Tat-TAR interaction
(7).
Within the activation domain are the acidic proline-rich domain, cysteine-rich
domain, and the core domain. These three domains are responsible for the interaction
between Tat and CyclinT1 (8). The cysteine-rich domain contains six cysteines and one
histidine and is critical for zinc binding and Tat-mediated transcription (9).
The other two main domains of Tat are the glutamine-rich domain at amino acids
87-101 encoded by the exon 2 (7). The glutamine-rich domain and exon two do not
contribute greatly to the ex vivo propagation of HIV-1 (7). However, those are highly
conserved in various HIV-1 isolates, indicating their biological importance (7). In
addition, exon two has been shown to be significant in several biological assays,
although its exact function is not known (7). It has been hypothesized that an
arginine-glycine-aspartate (RGD) motif within the exon two mediates Tat binding to cell
surface integrins (10 ).
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Overall, the Tat amino acid sequence has low hydrophobicity and a high net
positive charge (10). Analysis using various algorithms indicated that the protein is
natively unfolded only at the region of residues 42-75 (10). CD spectropolarimetry
confirmed the lack of secondary structure within the majority of the protein (10). 1H
Spectroscopy showed that the Cys-rich region consists of β-turns, while the Gln-rich
region consists of α-helices (10). The benefit of Tat being unfolded is that it has a much
larger surface area, allowing it to have multiple interactions with different molecules
(10). Upon interaction with a binding partner, Tat becomes folded in its proper 3D
structure (10).

Structure of the P-TEFb Complex
The complex structure of CDK9/CycT1 was determined using a truncated variant of
CycT1 that contains only the two N-terminal cyclin box repeats and their flanking helices
(11). While this structure showed its similarities to other structures of cell cycle
CDK/Cyclin pairs, distinct differences were observed in regards to the relative
orientation of the subunits to each other (12). The interaction interface area between
CDK9 and CycT1 within P-TEFb is about 40% smaller than that of CDK2/Cyclin A (12).
Within the CDK9/CycT1 complex, the N-terminal helix HN of CycT1 adopts a
conformation where it is directed towards the solvent, resulting in unique interactions
between the N terminus of CycT1 and CDK9 and the N-terminus of CDK9 and CycT1
(11). Within the P-TEFb complex, Cyclin H3, H4, and H5 helices interact with the CDK
αC and β4 strand to stabilize its active conformation (11). The residues are presented in
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figure 3. The structure of P-TEFb shows increased flexibility in the C-terminal helix that
flanks the cyclin box repeat as compared to other CDK/Cyclin pairs (12).
After autophosphorylation of CDK9, a mixture of unphosphorylated, mono-, di-,
and tri- phosphorylated forms was obtained (11). Tandem Mass Spectroscopy identified
the new autophosphorylation sites, Ser347, Thr362, and Thr363, in addition to Thr186
(11). Autophosphorylation of Ser362 and Ser363 is mutually exclusive, meaning that
tri-phosphorylated CDK9 has either pThr186, pSer147, and pThr362 or pThr186,
pSer147, and pThr363 (11). Generation of a T186A mutant indicates that Thr186 is
responsible for phosphorylating the CTD substrate of RNA pol II (11). The functions of
the other autophosphorylation sites within the C-terminal of CDK9 remain to be
investigated (11).

Structure of the Tat/P-TEFb Complex
To initiate transcription elongation of HIV-1, P-TEFb must interact with the Tat protein,
forming a complex. Upon studying the structure of the Tat/P-TEFb complex (PDB ID:
3MI9), it was determined that Tat forms an extended conformation through interactions
with Cyclin T1 (8). Upon binding, P-TEFb buries 3,499 A2 of its surface area within the
complex, 88% of which is on CyclinT1 and 12% is on CDK9 (8). The amount of surface
buried is very large, double the average value for stable protein-protein interactions
(13). This indicates that the complex is extremely stable, relative to other protein-protein
interactions. Although the interaction between CDK9 and Cyclin T1 is smaller in P-TEFb
than in other complexes, the interaction with Tat makes up for this as Tat inserts itself in
the groove at the interface of the two subunits (11). The interaction between Tat, CDK9,
and CyclinT1 increases the stability and the activity of the complex.
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Upon binding to P-TEFb, the ordering of the residues within Tat occurs. The
activation domain, which consists of residues 1-49, becomes ordered, while the rest of
the protein remains fluid (8). The acidic proline rich domain takes on an extended loop
conformation with two β turns separated by a small coil (8). The U-shaped region sits in
the depressions formed by the two cyclin repeats of CyclinT1 (8). One of the β turns
within the acidic proline-rich domain also contacts the T-loop of CDK9 (8). Experiments
show that mutations or deletions within these regions result in a nonfunctional Tat (14).
The cysteine-rich and core domains are more structured with a coil, two helices, a tail
and two bound Zn ions (8). These regions also interact with the depression formed by
the cyclin repeats of CyclinT1 (8). A Zn-mediated bridge between Cys261 of CyclinT1
and Tat is also essential to the stability of the complex (8). The second Zn ion is
coordinated by Cys25, Cys27, and Cys30 of Tat, as well as Cys261 of CyclinT1 (8).
The Tat and P-TEFb interaction is also mediated by several hydrophobic
interactions. Within Tat is a hydrophobic region that consists of the N-terminal
methionine and amino acids in the cysteine-rich domain and the core domain (8). This
region of Tat packs closely with the hydrophobic residues of Cyclin T1, as shown in
Figure 4a, and the hydrophobic residues of CDK9 (8). Tat also forms intermolecular
hydrogen bonds with Cyclin T1 and CDK9, as shown in Figure 4b and Table 1 (8).
There are many more intermolecular hydrogen bonds within the Tat/P-TEFb complex
than the six intramolecular hydrogen bonds within Tat, indicating that the overall
confirmation of Tat is predominantly determined and stabilized by P-TEFb (8).
Within the Tat/P-TEFb complex, CycT1 is a crucial element for Tat-mediated
transcriptional activation of HIV-1. Without the Tat-TAR recognition motif (TRM) within
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CycT1, the Tat-CycT1-TAR ternary complex is unable to form (4). CycT1 also has a
N-terminal cyclin box that is essential for binding to CDK9 or Tat (15). Within this region
are amino acids that inhibit binding with other proteins upon substitution (16). For
example, the Val107Glu substitution abolishes the binding of CycT1 to CDK9, TAR, and
HEXIM1, thereby decreasing the HIV transcription (16).

Regulation of HIV-1 Transcriptional Elongation
Tat-mediated Transcriptional Regulation
HIV-1 transcription is mainly regulated through the interaction of P-TEFb with the critical
protein-RNA complex, composed with the viral transactivator Tat and the nascent HIV-1
TAR RNA (17). The process of Tat-mediated HIV-1 transcriptional elongation is an
example of a complex, multistep mechanism that requires the interaction of many
different proteins and transcription factors.
The first step of elongation is for the binding of the basic “ARM” motif of Tat to the
UCU bulge of TAR RNA near its major loop (17). The cellular factor
P300/CBP-associated factor (PCAF) acetylates Tat on Lys28 in order to recruit P-TEFb
to the Tat-TAR complex (18). The CDK9 subunit of P-TEFb is responsible for
phosphorylating Ser2 within the 7 amino acid repeat, YSPTSPS, of the carboxy terminal
domain (CTD) of RNA polymerase II (3). This phosphorylation converts RNA
polymerase II from the paused form into the actively elongating form. In addition, CDK9
phosphorylates DSIF on its Spt5 subunit and NELF on its NELF-E/DR subunit (19).
Upon phosphorylation, DSIF is converted from a negative elongation factor into a
positive elongation factor and NELF, which acts as an inhibitor, is removed from the

11

HIV-1 promoter (17). These modifications by CDK9 are depicted in Figure 5. The Lys50
residue of Tat must be acetylated by the cellular proteins hGCN5 and/or p300 to remove
the Tat/P-TEFb complex from the TAR RNA, which promotes its transfer to the RNA
polymerase II dependent transcriptional elongation complex (20). Throughout
elongation, P-TEFb and Tat frequently associate and dissociate from each other,
allowing large expression of HIV-1 genes (21). To conclude elongation, the lysines of Tat
are deacetylated by sirtuin 1 (SIRT1), which causes Tat to be released from RNA
polymerase II (22). The released Tat proteins are then recycled, so that another round
of HIV-1 transcription can be initiated (17).

Negative Regulation by the 7SK snRNP Complex
In addition to binding with Tat, P-TEFb interacts with the 7SK ribonucleoprotein (RNP),
comprised of 7SK snRNA, hexamethylene bisacetamide-inducible 1/2 (HEXIM1/2),
methyl phosphatase capping enzyme (MePCE) and the La ribonucleoprotein domain
family member 7 (LARP7) (17). In latency infected cells, the majority of the P-TEFb is
found complexed with 7SK RNP (17). Upon binding to 7SK RNP, the activity of P-TEFb
is inhibited by HEXIM 1/2, making it a negative transcriptional regulatory complex (17).
HEXIM 1/2 hides the catalytic site of CDK9, so that it is unable to phosphorylate the
Ser2 on the CTD of RNA polymerase II and the other transcription factors associated
with transcriptional elongation (23). The inactive P-TEFb/7SK RNP complex is recruited
to the proximal-promoter region prior to transcription initiation and TAR RNA production
(24). This allows for the immediate initiation of transcription upon P-TEFb being
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released from 7SK RNP (17). Figure 6 shows the function of 7SK snRNP within the
process of HIV-1 transcription.
The first 18 amino acids within HEXIM1 are both necessary and sufficient for its
binding to P-TEFb and inhibition of the CDK9 kinase activity (17). Within this region of
HEXIM1 are multiple positively-charged amino acids, similar to the “ARM” of Tat (17).
The “ARM” of Tat, which is responsible for the binding of TAR RNA, contains an
additional arginine residue, R52, that functions in the conformational remodelling of TAR
RNA and 7SK snRNA (25). When Tat comes into contact with 7SK snRNA, HEXIM1 is
simultaneously released from the complex, interrupting the inhibition of the kinase
activity of P-TEFb (17). Tat then binds to TAR RNA and recruits the unbound, activated
P-TEFb to initiate HIV-1 transcriptional elongation (17). Furthermore, by Tat and 7SK
snRNA interacting, future reassembly of the 7SK snRNP complex is prevented and so
P-TEFb is inactivated (25).

Regulation by BRD4
Active P-TEFb within the cell is associated with the bromodomain protein BRD4, which
promotes transcriptional elongation (17). Upon interaction between the C-terminal
domain of BRD4 and P-TEFb, P-TEFb is displaced from the 7SK snRNP complex to
become activated (26). In addition, using its C-terminal domain, BRD4 recruits P-TEFb
and interacts with the mediator complex (17). However, prior report has shown that
BRD4 overexpression decreases the interaction between Tat and P-TEFb (27). As a
result, BRD4 interferes with the Tat-mediated HIV-1 transcription. The decrease in
interaction is caused by BRD4 competing with Tat for binding to P-TEFb (17). This
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shows that BRD4 plays both a positive and negative role in the regulation of HIV-1
transcription (17).

Post-translational Modifications of the Tat/P-TEFb Complex
Modifications involved in Tat Transcriptional Activity Regulation
Post-translational modifications of Tat alter its interaction with TAR RNA. Due to being
reversible in nature, post-translational modifications allow for rapid fine-tuning of Tat
function during the HIV transcription cycle (12). Many of the modifications are found in
the “ARM” region of Tat as shown in Figure 5, further supporting its important role in
mediating interactions with TAR RNA and CycT1 (12).
Some of the post-translational modifications turn Tat off, inhibiting HIV-1
transcription. Examples of such modifications include arginine methylation by the
methyltransferase PRMT6 and lysine methylation by SETDB1 (12). Within the nucleus,
PRMT6 monomethylates and asymmetrically dimethylates arginines in Tat (28).
Specifically, PRMT6 methylates Arg52 and 53 within the Tat “ARM” (29). As a result of
methylation, the Tat/TAR/P-TEFb complex is unable to form, inhibiting the function of Tat
(29). Similarly, methylation of Lys50 and 51 by SETDB1 also inhibits the formation of the
Tat/TAR/P-TEFb complex (30). SETDB1 functions by either di- or tri-methylating the
lysine residues (31). To date, it is unknown how the addition of methyl groups on either
the arginine or lysine residues in Tat interferes with binding to TAR and P-TEFb (12).
However, it is clear that methylation does not neutralize the positive charge on the
amino acid residue (12). A possible hypothesis is that the addition of the methyl group
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sterically hinders the tight interaction with nucleotides in the hairpin loop of TAR RNA
(32).
Other post-translational modifications turn Tat on, activating HIV-1 transcription.
Modifications include phosphorylation, polyubiquitination, acetylation, and
monomethylation, and have been found to occur across the entire protein, from the Nto C- terminal domains (12). The first activating modification observed was the
phosphorylation of HIV-1 Tat by the interferon-induced, double-stranded
RNA-dependent serine/threonine protein kinase, PKR, and the cell cycle-dependent
kinase CDK2/cyclin E complex (33). Polyubiquitination of Tat has a non-proteolytic and
activating effect on the protein, despite it commonly signaling protein degradation by the
proteasome (34). The proto-oncoprotein Hdm2 is responsible for the ubiquitination of
Lys71 in the C-terminal domain (34). While Lys71 is the main target for ubiquitination, it
is most likely not the only site (12). A third activating modification is the acetylation of
Lys28, which is located in the cysteine-rich region (18). Once Lys28 is acetylated by
PCAF/KAT2B, Tat’s affinity to bind with TAR and P-TEFb increases significantly (35).
The surrounding cysteines within the cysteine-rich domain play a critical role as acetyl
acceptors because of their reactive sulfhydryl groups, allowing acetylation of Tat to
occur without the enzyme present (36).
Monomethylation of Lys51 by the aminomethyltransferase Set7/9 within the
“ARM” region of Tat also activates the protein (37). Since this residue is involved in both
activating and deactivating modifications, it is evident that Lys51 plays an important role
in the Tat transactivation cycle (12). Using the structural data from the EIAV
Tat/TAR/CycT1 complex and extrapolating the structure for HIV-1 Tat, it was determined
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that Lys51 interacts with the bases of the first Watson-Crick base pairings near the
hairpin loop of TAR RNA (12). Di- or trimethylation of Lys51 may interfere with this
interaction, which explains the resulting inhibition of transcription due to Tat being turned
off (37). On the other hand, monomethylation strengthens the Tat, TAR and CycT1
complex formation, activating HIV-1 transcription (37).

Modifications that Regulate P-TEFb Activity
CyclinT1, CDK9 and HEXIM1 are reversibly phosphorylated, which affects the activity of
P-TEFb (38). Autophosphorylation experiments show that CyclinT1 is a likely substrate
of the kinase CDK9, making it a phosphoprotein (39). It is determined that the
phosphorylation occurs past residue 298, as phosphorylation does not occur in
autophosphorylation experiments using a C-terminally truncated CyclinT1 protein (11).
The exact site of phosphorylation and its role in transcription remains to be determined.
HEXIM1 is phosphorylated by the AKT/protein kinase B in the
phosphoinositide-3-kinase (PI3K) signaling pathway (40). Amino acids T270 and S278
are the sites of the phosphorylation, both of which belong to the cyclin T-binding domain
(38). Experimentation determined that treatment with HMBA led to the HEXIM1
phosphorylation by PI3K/AKT and the dissociation of P-TEFb from the 7SK snRNP
complex (38). As a result, HIV transcription is activated.
HMBA also regulates the phosphorylation of CDK9, which occurs at residues
T29, S175, T186, S347, T362, and T363 (38). T186 is found at the tip of the conserved
T-loop in CDK9 and is critical to the proper functioning of CDK9 (38). However, it is
unknown which kinase phosphorylates T186 (38). In order to get maximal activation of
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CDK9, phosphorylation causes a conformational change in the T loop to allow for the
substrate and ATP to enter into the catalytic site (41). T186 is phosphorylated in the
inactive P-TEFb complex, which serves to prepare the CDK9 for rapid activation upon
dissociation from HEXIM1 (42). In addition, phosphorylated T186 plays an important
role in the formation of the 7SK snRNP complex (42). When HMBA treatment occurs
and P-TEFb is activated, T186 is dephosphorylated, further supporting the finding that
phosphorylation of T186 in CDK9 is necessary for the formation and maintenance of the
7SK snRNP (38).
Phosphorylation of S175 is also critical in the interaction between P-TEFb and
BRD4 (43). It still needs to be determined which kinase phosphorylates S175 and the
mechanism by which it is phosphorylated (38). Phosphorylation of S175 results in
conformational changes in P-TEFb that promotes the binding of BRD4 to CyclinT1 more
efficiently (38). By being phosphorylated, S175 promotes the phosphorylation of RNA
polymerase II CTD, resulting in the promotion of HIV-1 transcription (44). When S175 is
mutated to alanine, the CDK9 kinase activity was inhibited (44). On the other hand,
when S175 is mutated to aspartic acid, which mirrors serine with the hydroxyl group, it
does not have the same inhibiting effect (44).

Other Transcriptional Factors Employed by the Tat/P-TEFb Complex
Super Elongation Complex (SEC)
Affinity purification led to the identification of the complex containing CDK9 and Tat (12).
As a result, the transcription factors and cofactors ELL2, AFF4, ENL, and AF9 were
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determined to be associated with the Tat/P-TEFb complex (45). The complex consisting
of these factors is known as the super elongation complex (SEC).
The SEC subunits ELL1/2 are positive elongation factors and function by
triggering RNA polymerase II’s processivity by aligning the 3’ OH of the nascent mRNA
with the catalytic site and preventing backtracking of the enzyme (46). The identification
of SECs leads to the statement that ELL1/2 and P-TEFb are utilized separately within
the cell being debunked as both are used simultaneously within the complex (12). To
recruit the SEC to the HIV-1 LTR, Tat interacts with TAR RNA (12). Tat then binds to the
scaffold protein AFF4 in order to increase the affinity between AFF4 and the CyclinT1
subunit of P-TEFb (47). The end result is the contact of P-TEFb and ELL2 with the RNA
polymerase II and transcriptional activation (45). Tat also functions by stabilizing ELL2,
which aids in the formation of the SEC complex (45). Without it, ELL2 is rapidly
degraded by the proteasome when the transcription factor is ubiquitinated by the E3
ubiquitin ligase Siah1 (45).
The SEC has also been shown to function in the absence of Tat. In this case, the
scaffold protein AFF4 acts as the mediator between SEC and P-TEFb, filling in for Tat in
its absence by stabilizing ELL2 and promoting SEC complex formation (45).

SEC-mediated Regulation by Ssu72
Ssu72 is a CTD phosphatase that further regulates the SEC-mediated transcriptional
elongation of HIV-1 (17). Ssu72 functions by aiding in the dephosphorylation of Ser5
and Ser7 on the RNA polymerase II CTD without interfering with the phosphorylation of
Ser2 (17). An experiment using a Ssu72 mutant resulted in the accumulation of RNA
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polymerase II Ser(P)5 as evident in Figure 7 (48). This finding led to the conclusion that
the function of Ssu72 is to dephosphorylate Ser(P)5 during active transcription (48). In
addition, the accumulation occurred near the 5’ end of the genes, which communicates
that Ssu72 acts early on in the transcription cycle (48). Similar results were found
regarding Ssu72 and Ser7 on the CTD of RNA polymerase II (48).
Ssu72 is also involved in the regulation of the phosphorylation state of Ser2 (48).
This was determined by performing ChiP using the 8WG16 antibody, which binds to the
unphosphorylated Ser2 on the CTD of RNA polymerase II (48). When Ssu72 is knocked
down, the 8WG16 ChIP signal decreases as shown in figure 8, indicating that the
Ser(P)2 levels increase (48). Ssu72 could be involved in the indirect regulation of Ser2
phosphorylation by recruiting and activating the Ser(P)2 phosphatase, Fcp, although it
is not known (48).
Through the involvement in the phosphorylation of Ser5 and Ser7 directly and
regulation of Ser2, the shift from transcriptional pausing to transcriptional elongation is
promoted. Ssu72 is recruited along with P-TEFb and the SEC complex by Tat and
results in significantly increased rates of HIV-1 transcriptional elongation (48). Ssu72 is
not essential for HIV-1 transcription, however. It is hypothesized that the absence of
Ssu72 allows for Ser(P)5 dephosphorylation by another CTD phosphatase due to the
fact that Ssu72 degradation did not result in Ser(P)5 accumulation (48). However,
catalytically inactive Ssu72 does result in the accumulation of Ser(P)5 possibly because
the ability to associate with the CTD of RNA polymerase II is maintained, inhibiting other
CTD phosphatases from making contact (48).
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Next Steps: Therapeutic Approaches for Treating HIV-1
What is Latency?
The main reason that HIV-1 is unable to be cured is the persistence of the virus within
latently infected cells (6). A latently infected cell is one that the HIV-1 DNA has become
integrated into the host's genome, but does not actively replicate (6). Therefore, the
DNA is invisible to the host’s immune system, the cellular machinery that functions to
fight disease, and antiviral drugs (6). However, not every cell within an infected
individual reaches latency. It is estimated that one in every 106 resting CD4+ T cells
contains HIV proviruses that are fully integrated and transcriptionally silent. Therefore,
there are roughly 107 latently infected T cells (6). Latently infected cells exhibit high
persistence of HIV even though there are relatively few of them due to their extremely
long half-life (6). The half-life of latent cells were determined to be 44 months by
conducting a longitudinal analysis of the decay rate (6). As a result, it would take more
than 60 years of uninterrupted treatment to naturally eradicate the reservoir of latent
cells (6).

Mechanisms of Latency
The mechanism by which cells become latent involves the exploitation of cellular and
viral factors in order to suppress transcription of the viral promoter LTR (6). While the
mechanism is not entirely known, there are many factors that have been found to have
an effect on the silencing of the integrated HIV-1 proviruses. Such factors include the
site of viral integration, the chromatin organization at the viral promoter, transcriptional
interference, the pool of available cellular cofactors required for HIV expression and
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suboptimal amounts of the viral transactivator Tat, the presence of microRNA and
mechanisms of RNA interference (6).
For latency to occur, integration of the provirus must occur. Interactions between
the pre-integration complex (PIC) and host factors present for active gene expression
suggest that transcriptional interference results in the latency establishment (6). The
orientation of the interaction between the provirus and the host gene has a large effect
on the resulting interference (6). If they are oriented in the same way, the promoter can
become blocked through the displacement of a constitutively expressed transcription
factor from the host gene (6). If they are oriented in opposite ways, the RNA polymerase
II complexes of the host and viral promoters collide, resulting in early termination of
transcription (6).
The chromatin modifications present in the host’s genes influences the ability for
the HIV-1 provirus to remain dormant by interfering with the expression of their viral
genes (6). It has been found that when the provirus genes are silenced within the host
genome, Nuc0 and Nuc1, which are located upstream of the modulatory region and
downstream of the core promoter and cis-regulatory elements, respectively, bind with
the 5’ long terminal repeat (LTR) of the provirus (6). The binding sites for key
transcription factors in HIV-1 gene expression become blocked by the nucleosomes,
inhibiting its expression (6). Nuc1 resembles silent heterochromatin with its lysine 9
trimethylated histone 3 (H3K9me3), heterochromatin protein 1 (HP1) and low histone
acetylation (6). In order for transcription of HIV-1 genes to occur, Nuc1 must be
epigenetically modified or removed from the host genome (6).
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Histone deacetylases (HDACs), in particular HDACs 1, 2, and 3, and histone
methyltransferases (HMTs) further reinforce latency through their recruitment to the viral
promoter by host factors (6). The host factors that recruit HDAC1 include YY1, Sp1, and
NF-κB homodimers p50/p50 (6). Other factors, such as Ras-responsive binding factor 2
(RBF-2), along with the transcription factor TFII-I, recruit HDAC3 (6). The HMTs EZH2,
G2a, and SUV39H1 methylate histone H3 at lysine 9 (H3K9) and lysine 27 (H3K27) to
silence the HIV-1 genes (6). These methods of inducing latency are depicted in Figure
9.
In HIV-1 latent cells, the transcription start site is also flanked by two CpG
islands, cytosine residues that are hypermethylated (6). The role of the CpG islands is
still under investigation. However, it has been shown that the transcriptional repressor
methyl-CpG binding domain protein 2 (MDB2) and HDAC2 bind to one of the CpG
islands (6).

Therapeutic Approaches to Overcome Latency: “Shock and Kill”
Within the “shock and kill” approach to overcoming latency, viral production has to be
restarted and then, the virus can be killed (6). However, this is a challenge as the
expression of the promoter is tightly restricted (6). One possible way to do this is by
remodeling the chromatin using acetylation and methylation inhibitors as shown in
Figure 9 (6). The HDAC inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)
selectively inhibits Class I HDACs (6). Experimentation has shown that SAHA is
effective at activating latently infected cells by inducing histone H3 acetylation and
transcription of the HIV RNA in vivo and ex vivo (6). Therefore, the presence of the drug
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can hinder the latent infection within a proportion of the reservoir of latent resting CD4+
T cells (6). The effectiveness at the hindrance of SAHA is currently unknown as multiple
dose clinical studies are still being performed (6). The use of SAHA is limited to short
term exposure due to its mutagenicity in vivo in standard bacterial assays (6). Other
HDACis, such as Droxinostat, targets HDAC3 (6). The benefit of these other HDACis is
their increased specificity and reduced toxicity to the body (6).
The advantages of using HDACis to awake HIV-1 cells from latency are that they
inhibit the proliferation and activation of T cells, remain active in many different types of
cells, and have resulted in extensive testing as anticancer drugs (6). However, the exact
mechanism of how they function is still to be determined. To date, researchers do not
know the best dose and administration schedule in order to purge the pool of latent
HIV-1 cells, while limiting toxicity. Toxicity is a foreseeable issue as HDACis can target
molecules other than HDACs, resulting in the increase in acetylation of unintended
histones (6). When histones are unintentionally acetylated, the expression of the
resulting gene is affected in an uncontrolled manner and could manifest deleterious
effects.
Another “shock and kill” method is to reintroduce and/or activate the transcription
factors that are heavily down regulated in latently infected cells (6). The drugs contained
within this category typically induce protein kinase C (PKC) and NF-κB/NF-AT pathways
and P-TEFb stimulators, which get sequestered in inactive complexes or expressed in
very low levels when latency is reached (6). Bryostatin-1 activates PKC and 5’
adenosine-monophosphate-activated kinase (AMPK) pathways (6). This approach has
been shown to be effective on its own and in combination with HDACis. Bryostatin-1 is a
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beneficial treatment option because it is nontoxic in vitro and it does not result in the
proliferation of T cells (6). Bryostatin-1 also prevents the spread of HIV-1 infection to
susceptible cells through the down regulation of CXCR4 and CCR5 coreceptors, which
are involved in the fusion of the viral RNA with the host cell (6). A surprising result of
this treatment is the stimulation of elongation due to the increase of P-TEFb (6). This
reinforces the other activators, such as HDACis if treated in parallel with bryostatin-1
(6). On the other hand, similar to HDACis, these compounds do not have high
specificities for their targets and thus, can result in overactivation of unwanted cellular
products and coinciding negative side effects (6).
A common way to reactivate latent cells is to increase the interaction between
P-TEFb and the promoter of the viral DNA. This can be done in two ways: introducing
Hexamethylene bisacetamide (HMBA), a P-TEFb activator, or inhibiting BRD4 (6).
HMBA is able to remove cells from latency by activating the PI3K/Akt pathway and
phosphorylating HEXIM1 (6). Therefore, P-TEFb is recruited to the promoter of the
HIV-1 gene in a Sp1-dependent manner and transcription can begin, even in the
absence of the Tat protein (6). Further benefits of HMBA are the increased amount of
CDK9 and free P-TEFb in the nucleus, as well as prevention of the T cell activation and
spread of HIV-1 infection to neighboring cells (6). The downside of using HMBA as a
treatment is that its efficiency in reversing latency is rather low and it is metabolized very
rapidly. Studies have shown that in order to reach detectable drug levels and for a
significant amount of activation to occur, HMBA has to be continuously infused (6).
P-TEFb can also be recruited to the promoter by the inhibition of BRD4 (6). While
BRD4 is involved in the recruitment of CDK9 to phosphorylate the CTD of RNA
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polymerase II, it is also an inhibitory factor if overexpressed, as discussed above. JQ1 is
a small, inhibitory molecule of bromodomain and extraterminal (BET) protein family with
high specificity for BRD4 (6). By treating infected cells with JQ1, proviral expression is
induced since the interaction between BRD4 and P-TEFb is blocked, allowing Tat to
bind to P-TEFb at the promoter (6). Often, JQ1 is given in parallel with prostratin, a drug
with similar function to Bryostatin-1, to suppress T cell proliferation by down regulating
the T cell activation genes, such as CXCR4, and upregulating the chromatin
modification genes, such as SIRT1, HDAC6 and lysine demethylases (KDMs) (6). JQ1
manifests very low toxicity to the cells outside of the intended purpose (6).
Despite the benefits of JQ1, studies in patients have not resulted in conclusive
findings that it reactivates latent cells (6). One study showed that JQ1 did reactivate the
provirus in one out of three patients (49). However, another study showed that JQ1 had
no significant effect when given by itself or even when given in combination with
prostratin (50). Further research into the activity of JQ1 and its mechanisms are
required to determine if it can be a possible treatment method.

Future Directions
Much progress has been made in understanding the mechanism by which HIV-1 enters
CD4+ T lymphocytes and replicates using the host’s cellular machinery. However, a
cure for HIV-1 has yet to be discovered due to challenges that come with latently
infected cells. Many therapeutics have been studied, including “Shock and Kill,” which
was discussed above, immune-based therapies, and gene therapy approaches (6). All
therapeutics studied thus far result in the same challenge: the cells that harbor the
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integrated and replication-competent virus re-infect other cells in the system as soon as
therapy is interrupted (6). Future studies must focus on developing therapeutics that not
only functionally control or eliminate the viral reservoirs but also eradicate them (6).
Since eradication is not possible at this time, studies should focus on making
treatment less demanding for patients. All current treatments require daily dosing (51).
The development of a longer acting drug would be beneficial as patients wouldn’t have
to take the drug daily, decreasing the chance of them missing a treatment. Developing a
drug that only needs to be taken once a month is beneficial as it would require less
effort for the patient and it could also be less toxic and costly (51). The National Institute
of Allergy and Infectious Diseases (NIAID) has created an assortment of experts,
including clinicians and scientists, to investigate the possibility of a long-acting drug
(51). Thus far, two possible drugs have been identified, rilpivirine LA and cabotegravir
LA (51). The effectiveness of these drugs has yet to be determined in individuals that
have not adhered to the traditional strategy of daily treatments.
Another possible solution that should be investigated is the development of an
HIV therapeutic vaccine (51). The purpose of the vaccine is to stimulate the immune
system in already infected patients, so that future spread of HIV-infected cells is limited
(51). The result would be sustained viral remission without the need of taking a drug
daily. All previous efforts to develop an HIV therapeutic vaccine have been
unsuccessful. NIAID is focusing on advancing the immune response and its potency in
hopes that it will aid in the development of the vaccine (51).

Potential Study: Determining the Effectiveness of Rilpivirine LA and Cabotegravir
LA as Long-acting Drugs
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Due to HIV being a human specific disease, it is unable to infect mice, even if their cells
have the receptor CD4 (52). Therefore, humanized mice must be used in studies
involving the replication and treatment of HIV. Humanized mice models can be
developed by implanting either CD34+ stem cells or human tissue into immunodeficient
mice (52). Implantation results in the reconstitution of human hematopoietic cells, which
are responsible for the repopulatization of all different types of immune cells, including T
cells (52). Once mice are humanized, they are susceptible to HIV infection in the same
way that humans are (52). Therefore, a group of mice can be infected with HIV through
a vaginal, rectal or oral exposure (52).
The infected mice can be separated into 4 treatment groups to test the
effectiveness of rilpivirine LA and cabotegravir LA, the two possible long-acting drugs
identified by NIAID. One group will act as the control group and will not receive any of
the drugs of interest. The second group will receive the allotted dose of rilpivirine LA or
cabotegravir LA daily for six months. The third and fourth group of mice will receive the
same dose weekly and monthly, respectively, for 6 months. Every month, the infection in
the mice can be monitored in the peripheral blood plasma via a viral load assay (52).
The peripheral blood plasma contains the body’s T cells, which can be quantified to
determine the severity of the mouse’s immune system depression. The group of mice
that do not receive treatment should have the fewest T cells present in their blood. This
is because HIV infected cells are replicating with no interference, causing the immune
system to be the most depressed. The number of T cells present in the other 3 groups
will determine the effectiveness of rilpivirine LA and cabotegravir LA. Ideally, the mice
treated daily and monthly will have a similar number of T cells, indicating that the
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treatment drug is long-acting. Then, the patient would only need to take the drug
monthly to experience optimal relief. It is also important that the number of T cells
should also remain stable over time as the drug needs to prevent further replication of
HIV infected cells.

Conclusion
HIV-1 is an increasingly complex disease that affects millions of people worldwide.
HIV-1 destroys the immune system of the infected individual by replicating its genome
within CD4+ T lymphocytes. Once in the cell, transcription occurs by taking advantage
of the host cell machinery and virus specific proteins, allowing for the accumulation of
more HIV-1 RNA. HIV-1 transcription is the rate-determining step in the replication of the
provirus, making its understanding of utmost importance. The interaction between
P-TEFb and the viral transactivator Tat protein is critical in the activation of transcription,
which leads to it being highly regulated. Tat and P-TEFb interact mainly through
CyclinT1 and several hydrophobic interactions. Upon binding of the Tat-TAR recognition
motif and the N terminal cyclin box within CyclinT1 to Tat, the activation domain of Tat
changes conformation and becomes more ordered, further stabilizing the complex
(15,16). As well as being regulated by P-TEFb and the Tat-TAR complex, it is
secondarily regulated by 7SK RNA and other transcriptional factors, such as BRD4 and
the SEC. 7SK RNA sequesters P-TEFb in the 7SK snRNP complex, inhibiting it from
interacting with Tat and activating transcriptional elongation. This is a common
characteristic of latent cells. When a T cell becomes latent, the HIV-1 DNA has become
integrated into the host's genome and has stopped replicating, thus becoming invisible

28

to the cell's native defense mechanisms and any treatments. Numerous approaches to
overcome latency have been developed and tested, all of which restart viral replication
and allow for the viral DNA to be “killed.” Possible approaches include remodeling of the
chromatin within the cell, altering the amounts of transcription factors present within the
T cells, and increasing the interaction between P-TEFb and the promoter by either
adding HMBA or inhibiting BRD4. However, none of these have been completely
effective at eradicating the pool of latent cells, requiring further research before
determining if curing HIV-1 is possible.
Since eradicating HIV is not possible at this time, developing a less demanding
treatment option for the patient should be pursued. Possible options include long-lasting
drugs that only need to be taken weekly or monthly or therapeutic vaccines. Two
potential long-acting drugs identified are rilpivirine LA and cabotegravir LA (51). A
possible study to determine their effectiveness consists of infecting humanized mice
with HIV and treating them at different intervals to determine the number of T cells
present in the blood.
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Table 1. Intermolecular hydrogen bonds between P-TEFb and Tat
Reprinted from the Supplementary Material of Reference 8.
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Figure 1. HIV Replication Cycle
Infection of CD4+ lymphocytes begins when the envelope (Env) glycoprotein spike
makes contact with the CD4 receptor and the membrane spanning co-receptor
CC-chemokine receptor 5 (CCR5) (step 1). This leads to the fusion of the viral and
cellular membranes, causing the viral particle to enter into the cell (step 2). Partial
uncoating of the core shell (step 3) allows for reverse transcription to occur (step 4).
After the formation of the pre-integration complex (PIC), it is imported into the cell
nucleus (step 5) and PIC-associated integrase helps integrate the DNA into the host
cell's genome (step 6). Transcription of the viral DNA into RNA is mediated by RNA
polymerase II and positive transcription elongation factor b (P-TEFb) (step 7). The RNA
transcript exits the nucleus (step 8) and then is translated into viral proteins (step 9).
Together with proteins, the synthesized RNA is packaged into viral particles (step 10),
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which then bud from the host cell (step 11) and are released into the bloodstream (step
12). The enzyme protease either accompanies or soon follows release of the viral
particle to cleave it into maturity, making it infectious (step 13). Reprinted from
Reference 3.

Figure 2. Tat Functional Domains
The polypeptide that encodes for the Tat protein is 101 amino acids long and consists of
two exons and multiple functional domains. “ARM,” which is made up of residues 49-57,
is responsible for the binding of Tat to TAR RNA, nuclear localization of Tat and Tat
protein stability. The activation domain, which consists of the acidic/proline rich domain,
the cysteine -rich domain and the core domain, is responsible for the interaction
between Tat and CyclinT1 of P-TEFb. The glutamine-rich domain and exon two are
highly conserved among HIV-1 isolates and contribute to the propagation of HIV-1
transcription, although their exact function is still unknown. Reprinted from Reference 4.
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Figure 3. P-TEFb Stabilizing Interactions
The interactions between CDK9 and CyclinT1 are depicted above. CDK9 is shown in
green and CyclinT1 is shown in brown. Box A shows the key contacts between the two
subunits of P-TEFb. Box B also shows the contacts of CDK9 and CyclinT1, but with
respect to the CDK9 αC helix, which is shown in grey. Reprinted from Reference 11.

Figure 4a. Hydrophobic Interactions between P-TEFb and Tat
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P-TEFb and Tat form hydrophobic interactions upon binding. The extended hydrophobic
patch of Tat is shown interacting with the CyclinT1 residues Phe176, Leu184, Thr248,
and Pro249. Tat is depicted in grey and CyclinT1 is depicted in green. Reprinted from
the Supplementary Material of Reference 8.

Figure 4b. Intermolecular Hydrogen Bonds between P-TEFb and Tat
Intermolecular hydrogen bonds between P-TEFb and Tat to stabilize the complex.
CDK9, CyclinT1, and Tat are shown in yellow, green and grey, respectively. The
intermolecular hydrogens bonds are represented by dashed lines. Reprinted from the
Supplementary Material of Reference 8.
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Figure 5. Posttranslational Modifications within “ARM” region of Tat
Posttranslational modifications either inhibit or activate the association of Tat with TAR
RNA and P-TEFb. To inhibit translation, PRMT6 methylates Arg 52 and 53 and SETDB1
methylates Lys50 and 51 within the Tat “ARM.” The methylation of these residues
interferes with the interaction between Tat and P-TEFb, leading to the disassembly of
the complex. To activate transcription, CDK9, the kinase subunit of P-TEFb,
phosphorylates Ser2 of the CTD of RNA polymerase, NELF and DSIF. Other activating
modifications include polyubiquitination of Lys71 by proto-oncoprotein Hdm2,
acetylation of Lys28, and methylation of Lys51. Reprinted from Reference 12.
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Figure 6. 7SK snRNP in HIV-1 Transcription
7SK snRNP sequesters P-TEFb within the cell and inactivates it via HEXIM1, which
inhibits the kinase activity of CDK9. Tat recruits P-TEFb from the complex in order to
activate HIV-1 transcription. The association of BRD4 with activated P-TEFb can also
induce HIV-1 transcription if BRD4 is present in the optimal amount. Reprinted from
Reference 12.
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Figure 7. Dephosphorylation of Ser5 by Ssu72
Ssu72 functions by aiding in the dephosphorylation of Ser5. By knocking down Ssu72
phosphatase, the Ser(P)5 form of RNA polymerase II accumulates across the PMA1
and PYK1 genes. The accumulation of Ser(P)5 is evident by darker bands associated
with the ssu72-2 -37 degrees Celsius mutant as compared to the WT- 37 degrees
Celsius. Reprinted from Reference 48.

Figure 8. Misregulation of Ser2 by Ssu72 Knockdown
Knockdown of Ssu72 phosphatase leads to the misregulation of Ser2 phosphorylation.
The ssu72-td mutant has a recognizably different pattern of Ser2-P than the WT at the
primer pairs. The band darkness is quantified in part C, which further supports the
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finding as the darkness increases as the primer pair nears the 3’ end for the WT.
However, for the mutant, the band's darkness decreases. Reprinted from Reference 48.

Figure 9. Epigenetic Modifications of Tat used to Induce Latency
In order to silence HIV-1 transcription in latently infected cells, epigenetic modifications
are used. This can include the recruitment of histone deacetylases (HDACs) by the
NF-κB p50/p50 homodimer, which deacetylates histones at Nuc0 and Nuc1
nucleosomes, and the recruitment of histone methyltransferases (HMTs) like Suv39h1,
EZH2, and G9a, which methylate histones and CpG islands. HDAC, HMT, and DNMT
inhibitors are being explored to escape latency using the “shock and kill” strategy.
Reprinted from Reference 6.

